Dietary manipulation of platelet function.

Abstract:

:Activated platelets contribute to plaque formation within blood vessels in the early and late stages of atherogenesis, and therefore they have been proposed as risk factor for cardiovascular disease. Anti-platelet drugs, such as aspirin, are now the most prescribed pharmacological treatment in Europe. Certain dietary bioactives also beneficially affect platelet function, and with less side effects, albeit that effects are generally more subtle. Therefore, consumption of dietary bioactives could play a role in the prevention of atherothrombotic vascular disease. Here we review the efficacy of dietary treatment strategies, especially those involving certain dietary fatty acids and polyphenols, to modulate platelet function in healthy subjects or in patients with cardiovascular disease. Variation in study populations, small study sizes and lack of comparability between methods to assess platelet function currently limit robust evidence on the efficacy of dietary bioactives in healthy subjects or specific patient groups. Also, limited knowledge of the metabolism of dietary bioactives, and therefore of the bioavailability of bioactive ingredients, restricts our ability to identify the most effective dietary regimes to improve platelet function. Implementation of uniform point-of-care tests to assess platelet function, and enhanced knowledge of the efficacy by which specific dietary compounds and their metabolites affect platelet function, may enable the identification of functional anti-platelet ingredients that are eligible for a health claim, or combined treatment strategies, including both pharmacological anti-platelet treatment as well as dietary intervention, to tackle atherothrombotic vascular disease.

journal_name

Pharmacol Ther

authors

Bachmair EM,Ostertag LM,Zhang X,de Roos B

doi

10.1016/j.pharmthera.2014.05.008

subject

Has Abstract

pub_date

2014-11-01 00:00:00

pages

97-113

issue

2

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(14)00103-X

journal_volume

144

pub_type

杂志文章,评审
  • Targeting the glucagon receptor family for diabetes and obesity therapy.

    abstract::Diabetes is a debilitating disease characterized by chronic hyperglycemia and is often associated with obesity. With diabetes and obesity incidence on the rise, it is imperative to develop novel therapeutics that will not only lower blood glucose levels, but also combat the associated obesity. The G protein-coupled re...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.05.009

    authors: Cho YM,Merchant CE,Kieffer TJ

    更新日期:2012-09-01 00:00:00

  • Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?

    abstract::In addition to their prominent roles in the control of reproduction, estrogens are important modulators of energy balance, as evident in conditions of deficiency of estrogens, which are characterized by increased feeding and decreased energy expenditure, leading to obesity. AMP-activated protein kinase (AMPK) is a ubi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.03.014

    authors: López M,Tena-Sempere M

    更新日期:2017-10-01 00:00:00

  • Progranulin: a growth factor, a novel TNFR ligand and a drug target.

    abstract::Progranulin (PGRN) is abundantly expressed in epithelial cells, immune cells, neurons, and chondrocytes, and reportedly contributes to tumorigenesis. PGRN is a crucial mediator of wound healing and tissue repair. PGRN also functions as a neurotrophic factor and mutations in the PGRN gene resulting in partial loss of t...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.10.003

    authors: Liu CJ,Bosch X

    更新日期:2012-01-01 00:00:00

  • Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.

    abstract::Infection or sterile inflammation triggers site-specific attraction of leukocytes. Leukocyte recruitment is a process comprising several steps orchestrated by adhesion molecules, chemokines, cytokines and endogenous regulatory molecules. Distinct adhesive interactions between endothelial cells and leukocytes and signa...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.11.008

    authors: Mitroulis I,Alexaki VI,Kourtzelis I,Ziogas A,Hajishengallis G,Chavakis T

    更新日期:2015-03-01 00:00:00

  • Small molecules affecting transcription in Friedreich ataxia.

    abstract::This review concerns the development of small molecule therapeutics for the inherited neurodegenerative disease Friedreich ataxia (FRDA). FRDA is caused by transcriptional repression of the nuclear FXN gene, encoding the essential mitochondrial protein frataxin and accompanying loss of frataxin protein. Frataxin insuf...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.06.014

    authors: Gottesfeld JM

    更新日期:2007-11-01 00:00:00

  • Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

    abstract::Cardiovascular diseases cause more mortality and morbidity worldwide than any other diseases. Although many intracellular signaling pathways influence cardiac physiology and pathology, the mitogen-activated protein kinase (MAPK) family has garnered significant attention because of its vast implications in signaling an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.05.013

    authors: Javadov S,Jang S,Agostini B

    更新日期:2014-11-01 00:00:00

  • Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery.

    abstract::Postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery that occurs in up to 60% of patients. POAF is associated with increased risk of cardiovascular mortality, stroke and other arrhythmias that can impact on early and long term clinical outcomes and health economics. Many factors such as...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.06.009

    authors: Zakkar M,Ascione R,James AF,Angelini GD,Suleiman MS

    更新日期:2015-10-01 00:00:00

  • In utero drug therapy.

    abstract::Drug therapy directed toward the fetus would be intended for either treating a fetal disorder or improving the capacity for later intrauterine or postnatal adaptation. Most reported trials involve single cases or small numbers of fetuses receiving the drug transplacentally after the first trimester, but before attaini...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(93)90051-e

    authors: Rayburn WF,Payne GG Jr

    更新日期:1993-01-01 00:00:00

  • Targeting cell cycle regulation in cancer therapy.

    abstract::Cell proliferation is an essential mechanism for growth, development and regeneration of eukaryotic organisms; however, it is also the cause of one of the most devastating diseases of our era: cancer. Given the relevance of the processes in which cell proliferation is involved, its regulation is of paramount importanc...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2013.01.011

    authors: Diaz-Moralli S,Tarrado-Castellarnau M,Miranda A,Cascante M

    更新日期:2013-05-01 00:00:00

  • Serotonin receptors involved in antidepressant effects.

    abstract::The neurotransmitter serotonin (5-hdroxytryptamine; 5-HT) has been implicated in the pathophysiology and treatment of major depression since the serendipitous discovery of antidepressant drugs in the 1950s. However, despite the generalised use of serotonin-enhancing drugs, such as the selective serotonin reuptake inhi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.09.006

    authors: Artigas F

    更新日期:2013-01-01 00:00:00

  • Purinergic P2Y receptors: Molecular diversity and implications for treatment of cardiovascular diseases.

    abstract::Purinergic signaling, mediated mainly by G protein-coupled P2Y receptors (P2YRs), is now attracting attention as a new therapeutic target for preventing or treating cardiovascular diseases. Observations using mice with genetically modified P2YRs and/or treated with a pharmacological P2YR inhibitor have helped us under...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.06.010

    authors: Nishimura A,Sunggip C,Oda S,Numaga-Tomita T,Tsuda M,Nishida M

    更新日期:2017-12-01 00:00:00

  • Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds.

    abstract::Nongenomic estrogen signaling pathways involve extranuclear estrogen receptors or function independently from estrogen receptors. These pathways participate in neuroprotection elicited by the hormone. Additional nongenomic neuroprotective effects are attributable to antioxidant and antiinflammatory actions of estrogen...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.01.006

    authors: Prokai L,Simpkins JW

    更新日期:2007-04-01 00:00:00

  • Intestinal toxicity of non-steroidal anti-inflammatory drugs.

    abstract::We review the adverse effect of non-steroidal anti-inflammatory drugs (NSAIDs) on the small and large intestine. NSAIDs cause small intestinal inflammation in 65% of patients receiving the drugs long-term. The clinical implications of NSAID-induced enteropathy are that patients bleed and lose protein from the inflamma...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(94)90008-6

    authors: Bjarnason I,Macpherson AJ

    更新日期:1994-04-01 00:00:00

  • TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?

    abstract::The understanding of renal fibrosis in chronic kidney disease (CKD) remains as a challenge. More than 10% of the population of developed countries suffer from CKD. Proliferation and activation of myofibroblasts and accumulation of extracellular matrix proteins are the main features of kidney fibrosis, a process in whi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.10.003

    authors: Muñoz-Félix JM,González-Núñez M,Martínez-Salgado C,López-Novoa JM

    更新日期:2015-12-01 00:00:00

  • Getting to the heart of asthma: can "beta blockers" be useful to treat asthma?

    abstract::beta(2)-adrenoceptor agonists are the mainstay for the acute symptomatic treatment of asthma and provide effective bronchoprotection to a wide range of bronchoconstrictor agents. However, over the past 4 decades there has been a continuing debate concerning whether regular chronic treatment with these drugs may be doi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.04.009

    authors: Bond RA,Spina D,Parra S,Page CP

    更新日期:2007-09-01 00:00:00

  • Delta opioid receptors in brain function and diseases.

    abstract::Evidence that the delta opioid receptor (DOR) is an attractive target for the treatment of brain disorders has strengthened in recent years. This receptor is broadly expressed in the brain, binds endogenous opioid peptides, and shows as functional profile highly distinct from those of mu and kappa opioid receptors. Ou...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2013.06.003

    authors: Chu Sin Chung P,Kieffer BL

    更新日期:2013-10-01 00:00:00

  • Endothelins and sarafotoxins: physiological regulation, receptor subtypes and transmembrane signaling.

    abstract::The endothelins and sarafotoxins are two structurally related families of potent vasoactive peptides. Although the physiological functions of these peptides are not entirely clear, the endothelins are probably involved in pathophysiological conditions such as hypertension and heart failure. This review summarizes the ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(92)90030-4

    authors: Sokolovsky M

    更新日期:1992-01-01 00:00:00

  • Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

    abstract::Neutrophils form an essential part of innate immunity against infection. Cancer chemotherapy-induced neutropenia (CCIN) is a condition in which the number of neutrophils in a patient's bloodstream is decreased, leading to increased susceptibility to infection. Granulocyte colony-stimulating factor (GCSF) has been the ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107403

    authors: Abdel-Azim H,Sun W,Wu L

    更新日期:2019-12-01 00:00:00

  • Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.

    abstract::Proteolytic degradation of unwanted proteins by the ubiquitin-proteasome system (UPS) is critical for normal maintenance of various cellular functions. Parkinson's disease (PD), one of the most prevalent neurodegenerative disorders, is characterized by prominent and irreversible nigral dopaminergic neuronal loss and i...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.04.001

    authors: Sun F,Kanthasamy A,Anantharam V,Kanthasamy AG

    更新日期:2007-06-01 00:00:00

  • LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis.

    abstract::Lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1) was initially identified as the major receptor for oxidized LDL (OxLDL) in endothelial cells. Its inducible expression in macrophages and smooth muscle cell was also observed. LOX-1 is a Type II membrane protein with a typical C-type lectin structur...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(02)00236-x

    authors: Chen M,Masaki T,Sawamura T

    更新日期:2002-07-01 00:00:00

  • Cannabinoid analgesia.

    abstract::During the last decade, rigorous scientific methods have been applied to determine the effects of cannabinoids on nociceptive neurotransmission. Cannabinoids have been observed to markedly decrease signalling in specific neural pathways that transmit messages about pain. These effects were found to be due to the suppr...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(02)00252-8

    authors: Walker JM,Huang SM

    更新日期:2002-08-01 00:00:00

  • KRAS-related proteins in pancreatic cancer.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease with a high mortality rate. Genetic and biochemical studies have shown that RAS signaling mediated by KRAS plays a pivotal role in disease initiation, progression and drug resistance. RAS signaling affects several cellular processes in PDAC, includ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.09.003

    authors: Mann KM,Ying H,Juan J,Jenkins NA,Copeland NG

    更新日期:2016-12-01 00:00:00

  • Expression and function of efflux drug transporters in the intestine.

    abstract::A variety of drug transporters expressed in the body control the fate of drugs by affecting absorption, distribution, and elimination processes. In the small intestine, transporters mediate the influx and efflux of endogenous or exogenous substances. In clinical pharmacotherapy, ATP-dependent efflux transporters (ATP-...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.06.005

    authors: Takano M,Yumoto R,Murakami T

    更新日期:2006-01-01 00:00:00

  • Endothelial dysfunction in cirrhosis and portal hypertension.

    abstract::Portal hypertension (PHT) is a common clinical syndrome associated with chronic liver diseases; it is characterized by a pathological increase in portal pressure. Pharmacotherapy for PHT is aimed at reducing both intrahepatic vascular tone and elevated splanchnic blood flow. Due to the altered hemodynamic profile in P...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(01)00128-0

    authors: Cahill PA,Redmond EM,Sitzmann JV

    更新日期:2001-03-01 00:00:00

  • New drugs vs. old concepts: a fresh look at antiarrhythmics.

    abstract::Common arrhythmias, particularly atrial fibrillation (AF) and ventricular tachycardia/fibrillation (VT/VF) are a major public health concern. Classic antiarrhythmic (AA) drugs for AF are of limited effectiveness, and pose the risk of life-threatening VT/VF. For VT/VF, implantable cardiac defibrillators appear to be th...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.03.003

    authors: Thireau J,Pasquié JL,Martel E,Le Guennec JY,Richard S

    更新日期:2011-11-01 00:00:00

  • Complex regulation of thyroid hormone action: multiple opportunities for pharmacological intervention.

    abstract::The thyroid hormone (TH; 3,3',5,5'-tetra-iodothyronine and 3,3',5'-triiodothyronine) regulates growth, development, and critical metabolic functions. Thyroid diseases are among the most prevalent group of metabolic disorders in the Western world. TH exerts effects through complex biological pathways, which offer a wea...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(02)00219-x

    authors: Shi YB,Ritchie JW,Taylor PM

    更新日期:2002-06-01 00:00:00

  • Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis.

    abstract::Cardiovascular disease (CVD) continues to be a leading cause of death worldwide with atherosclerosis being the major underlying pathology. The interplay between lipids and immune cells is believed to be a driving force in the chronic inflammation of the arterial wall during atherogenesis. Atherosclerosis is initiated ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.08.012

    authors: Lacy M,Atzler D,Liu R,de Winther M,Weber C,Lutgens E

    更新日期:2019-01-01 00:00:00

  • Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.

    abstract::In mediating the transfer of cholesteryl esters (CE) from antiatherogenic high density lipoprotein (HDL) to proatherogenic apolipoprotein (apo)-B-containing lipoprotein particles (including very low density lipoprotein [VLDL], VLDL remnants, intermediate density lipoprotein [IDL], and low density lipoprotein [LDL]), t...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2003.10.001

    authors: Le Goff W,Guerin M,Chapman MJ

    更新日期:2004-01-01 00:00:00

  • Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.

    abstract::The past three decades have witnessed a welcome expansion of the therapeutic armamentarium for the management of pulmonary arterial hypertension (PAH). However, against this backdrop, there have been some notable disappointments in drug development. Here we use these as case studies to emphasize the importance of info...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.04.012

    authors: Lythgoe MP,Rhodes CJ,Ghataorhe P,Attard M,Wharton J,Wilkins MR

    更新日期:2016-08-01 00:00:00

  • Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.

    abstract::Primaquine is the only antimalarial drug available to clinicians for the treatment of relapsing forms of malaria. Primaquine development and usage dates back to the 1940s and has been administered to millions of individuals to treat and eliminate malaria infections. Primaquine therapy is not without disadvantages, how...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.03.011

    authors: Marcsisin SR,Reichard G,Pybus BS

    更新日期:2016-05-01 00:00:00